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as a specific T-cell lineage with immune regulatory function in the 1990s has revived the theory of active immune 
tolerance and uncovered a brand-new avenue for immunologic research. Tregs have been shown to play a 
crucial role both in health and diseases. Whilst tremendous advance has been made in our understanding of the 
expanding varieties of effector mechanisms exploited by Tregs, the migration phenotypes as well as the anatomic 
sites where Tregs exert immune regulation are scarcely investigated. Migration of Tregs to either the lymph 
nodes or peripheral tissues has been shown to be exclusively indispensable in Treg-mediated immune regulation 
in a variety of experimental models with specific gene-targeted mice. The once seemingly paradoxical findings 
are partly reconciled by later discovery of various Treg subsets with distinct migration/homing property as well 
as the inflammatory stage when Tregs come into play along an immune reaction. In our recent study, we 
investigated the migration characteristics of Treg cells by using the endothelial cell-based shear-stress flow assay 
that resembles the intravascular blood flow system. We found that both FoxP3-expressing Tregs and anergic T 
cells generated by blockage of costimulation factors, CD80 and CD86, exhibited a significantly decreased 
adhesion to endothelial cells as compared to antigen-activated effector T cells (66~88 % reduction). The less 
migration phenotype hinted inefficient tissue trafficking of the Tregs and suggested the lymph nodes as the 
anatomic site where Tregs optimally exerted immune regulation. To this speculation, an essential role of Treg 
lymph node positioning in exerting immune suppression was demonstrated by the inability of adoptively 
transferred Tregs to prevent footpad inflammation after blockage of lymph node entry of these Tregs by CCR7 
or CD62L Ab. Therapeutic modality targeting leukocyte migration has been a mainstay alternative for 
immunologic diseases. Important messages have arisen for treatments of this kind and Treg-based cell therapy 
that whilst inflammatory response can be harnessed by modulating the migration property of leukocytes, the 
relationship between Treg migration phenotypes and their immune regulatory function should always be taken 
into consideration. 
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Induction of peripheral tolerance as a therapeutic strategy 
for various immunological diseases has gained intense 
attention in the past two decades 
[1, 2]
. Among the
mechanisms identified in the operation of peripheral 
tolerance, Tregs are the most well-known key player 
[3, 4]
.
Tregs have been shown to exert immune suppression in a 
cell-contact dependent manner (Treg/APC or Treg/T-cell 
interactions), through the expression of PD1, CTLA-4, and 
TGF-, or via secretion of various humoral mediators, such 
as granzyme B, IL-10, IL-35 and etc 
[5-7]
. Additional
molecular mechanisms include the CD39/CD73 
ectonucleotidase that regulates ATP/AMP metabolism and 
adenosine production 
[8-10]
 as well as immune-regulatory 
microRNAs, such as miR-146a 
[11]
 (Fig 1A). Despite 
cumulating data have unraveled the mechanisms underlying 
Treg-mediated immune regulation, relatively scarce attention 
has been paid to where the immune suppression takes place 
in vivo. The issue arisen from this unsolved question is the 
feasibility and effectiveness of exploiting Treg cells in cell 
therapy for immunologic diseases. 
Leukocyte migration during inflammation 
Migration of leukocytes from the blood vessels into 
peripheral tissues is a crucial process both during 
immunosurveillance and inflammation. This response is 
orchestrated by sequential steps of leukocyte rolling, 
activation, firm adhesion to the endothelial cells (EC) and 
migration through the inter-endothelial junction and the 
vascular basement membrane 
[12, 13]
. These cellular events
require adhesive interactions between leukocytes and the EC 
and are largely mediated by selectin and integrin family of 
the adhesion molecules. As much as the magnitude of an 
inflammatory response could be modulated by harnessing the 
migration activity of the leukocytes, it is also theoretically 
feasible that immune tolerance can be achieved by targeting 
leukocyte migration.  
LN vs tissue localization of Tregs matters in immune 
regulation  
The long-held dogma of an immune response is 
characterized by recognition of foreign antigens in the 
periphery by antigen-presenting cells (APCs), such as the 
dendritic cells (DCs), followed by trafficking of these cells 
back to lymph nodes (LNs) to present processed antigens to 
T cells. The T cells, being activated by presented antigens, 
proliferate, and after providing help for B-cell antibody 
production, migrate out of LNs to enter the peripheral tissues 
where they secret cytokines to propagate the inflammatory 
cascade and execute cytotoxic effects. Treg cells are present 
not only in lymphoid organs but also in non-lymphoid 
peripheral tissues both at steady state and during 
inflammation. It is therefore equally logic for Tregs to exert 
their immune suppressive effects in either the draining LNs 
or the tissues, i.e. during immune induction or at the effector 
phase of an immune response. However, contradictory and 
mutually exclusive results have been shown by the studies 
using different experimental settings [14-17].  
CD62L and CCR7 are required for leukocyte LN 
trafficking. Blockage or deficiency of either CCR7 or CD62L 
prohibits LN positioning of leukocytes, including Tregs. In 
an allograft tolerance animal model, Tregs expanded 
selectively in the LNs of tolerant animals, but not in other 
anatomic sites or in animals with graft rejection. CD62L 
blockage of Treg LN localization led to graft rejection, 
whereas Treg LN sequestration by sphingosine 1-phosphate 
receptor agonist enhanced graft survival [18]. In line with 
these findings, previous studies have also showed that the 
CD62L+ LN-homing Tregs exerted suppressive function far 
better than their CD62L- tissue-homing counterparts, despite 
the two subpopulations were equally suppressive in vitro 
[19;20]. 
The same indispensable role of LN positioning in 
Treg-mediated immune suppression was demonstrated in 
CCR7-deficient mice [21]. Whist enhanced contact 
hypersensitivity was induced in these animals, the pathology 
was rescued by adoptive transfer of WT Tregs that were 
capable of LN trafficking [22]. Additional evidence supporting 
a crucial role of Treg LN positioning in immune tolerance 
comes from studies of autoimmune disease where 
preferential enrichment of Ag-specific Tregs in regional LNs 
was found in normal healthy mice [23]. These studies went on 
to demonstrate that strategic localization of Ag-specific 
Tregs in the draining LNs enabled persistent inhibition of 
pathogenic T-cell expansion selectively in regional LNs but 
not elsewhere [23, 24]. 
In our recent study, we found a less migratory phenotype 
of the Treg cells. CD4+CD25+ Treg cells and anergic T cells 
generated in vitro by blockage of costimulation factors 
exhibited significantly decreased adhesion to either activated 
endothelial monolayer or ICAM-1/ E-selectin-coated surface 
compared to activated effector T cells (Fig 2). The less 
migratory capacity of the regulatory T-cell population 
prompted our speculation of the in vivo positioning of Tregs 
for optimal immune regulation. It is conceivable that 
localization of Tregs in the lymphoid organs, instead of the 
peripheral tissues, would provide an optimal condition for 
cell contact-dependent immune regulation, and that at the 
priming or induction phase of an immune response. In 
addition, the low migratory capacity of the Tregs during 
inflammation would be insufficient to support adequate 
trafficking of these cells into inflammatory sites to exert  
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immune regulation. In concordant with this speculation, we 
found that CCR7 or CD62L blockage of Treg LN entry 
abrogated the immune suppressive effects of the Tregs, 
suggesting an essential role of Treg LN positioning in 
immune suppression which should be taken into account in 
Treg-based cell therapy [25].  
On the other hand, there are studies showing a crucial role 
for tissue localization of Tregs in immune regulation. In 
fucosyltransferase VII-deficient mice, migration of 
leukocytes to peripheral tissues was impaired due to lack of 
P-/E-selectin ligands. Tregs from fucosyltransferase 
VII-deficient mice failed to migrate to inflamed tissues and 
were unable to suppress skin inflammation as the WT Tregs 
did [16]. However, opposite outcome of impaired Treg tissue 
localization was demonstrated by studies using 7 
integrin-deficient mice. Although 7 integrin-deficient Tregs 
were incapable of immigrating to the intestines, they were 
nonetheless fully competent in preventing intestinal 
inflammation [17]. Adding complexity to these results, studies 
using various CCR-deficient mice proposed a sequential 
migration pattern of Treg cells in exerting immune 
suppression. These studies showed that Tregs were first 
recruited to the tissues and activated during inflammation 
before trafficking back to draining LNs to suppress immune 
activation [26].  
These seemingly contradictory results clearly demonstrate 
that both lymphoid organs and peripheral tissues can be the 
anatomic sites where Tregs suppress inflammatory responses 
[14-17]. These data also reflect the in vivo scenario that Tregs 
exert immune regulation at both the induction and effector 
phases of the immune reaction and lead to the revelation of a 
“division of labor” for Tregs - different Treg subsets with 
distinct migration phenotypes [14; 16, 20]. There are at least two 
Treg subpopulations - the re-circulating naïve-like and the 
inflammation-seeking effector-like Tregs - each defined by 
distinct homing/transmigration characteristics and 
differential expression of chemokine receptors and adhesion 
molecules (Fig 1B). It is therefore crucial for proper 
positioning of individual Treg subsets of distinct 
homing/transmigration property that might be selectively 
expanded along the course of an inflammatory reaction under 
various experimental settings. 
Tregs-EC crosstalk over leukocyte migration 
Induction of tolerance has been associated with thwarted 
Figure 1. Working model depicting Treg migration pattern and their immunosuppressive effects. (A) Mechanisms of Treg-mediated 
immune suppression: direct cell-cell contacts deliver inhibitory signals via PD1, CTLA4, TGF-, etc; secretion of immunoregulatory cytokines; 
metabolism of ATP/adenosine; regulation of chemokine and adhesion molecule expression and hence tissue trafficking of Teff; (B) Treg 
migration phenotypes and immune regulation. Tregs exert immune suppression at either the LNs or peripheral tissues. Individual Treg subsets 
expressing different profile of chemokine receptors and adhesion molecules exhibit distinct migration property. Whilst the naïve-like Tregs 
(nTreg) “home” to LNs, the memory-like Tregs (mTreg) preferentially migrate to inflamed tissues. Reprinted with permission [25].   
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T-cell migratory ability and retention of T cells at the site of 
tolerance induction 
[27-29]
. Intracellular signaling downstream
of chemokine receptors is controlled by the regulators of 
G-protein signaling (RGS) family and RGS-1 is known to 
inversely correlated with cell migration capacity. To this end, 
Tregs were shown to exhibit a less migratory phenotype than 
naïve T cells and expressed higher levels of RGS-1 than 
naïve T cells 
[28, 29]
. Furthermore, in the context of leukocyte
migration during inflammation, impeded trafficking of 
inflammatory leukocytes into peripheral tissues inevitably 
abrogates the inflammatory cascade. One mechanism 
reportedly exploited by Tregs to dampen inflammatory 
response is via regulating the migration of inflammatory 
leukocytes into inflamed tissues. Mechanistically, these 
effects are due to degradation of chemokines by CD26, the 
dipeptidyl peptidase IV, specifically expressed by Tregs and 
anergic T cells, which led to decreased adhesion-dependent 
leukocyte trafficking driven by chemokines 
[27, 30]
.
Leukocytes undergo phenotypic and functional changes 
after migration through the EC monolayer [31], it is therefore 
equally possible that leukocytes crosstalk with the EC or 
epithelia to modulate their phenotypes and functions. 
Although there are only few researches addressing the 
interaction between Tregs and EC or epithelia during 
inflammation, bidirectional crosstalks between EC and the 
Tregs have been shown. In one of these studies, CD8+ 
FoxP3+ suppressor T cells were shown to induce tolerogenic 
EC through mechanisms involving induction of the 
inhibitory receptors, immunoglobulin-like transcripts (ILT)-3 
and ILT-4, and down-regulation of costimulatory and 
adhesion molecules on the EC. The tolerogenic EC in turns 
suppressed activation of T helper and cytotoxic cells and 
elicited differentiation of new CD8+ FoxP3+ suppressor T 
cells [32, 33]. Another recent study addressed the same issue by 
using 7 integrin-deficient mice. In contrast to previous 
studies showing suppression of T cell-mediated colitis in 
Rag2-/- mice by 7-deficient Tregs 
[17], this study found 
aggravated DSS-induced colitis in 7 integrin-deficient mice 
that can only be rescued by WT Tregs but not 7-deficient 
Tregs [34]. In this study, WT Tregs were shown to migrate to 
the intestine and down-regulate epithelial expression of 
ICAM-1, which hampered recruitment of inflammatory cells 
and prevented progression of colitis. However, 7 
integrin-deficient Tregs failed to migrate to the intestine to 
exert this effect. The contradictory results between the two 
colitis models can be explained by nature of the 
inflammatory response elicited in the models, e.g. Ag-driven 
adaptive vs innate inflammation and hence the distinct roles 
or mechanisms of regulation exploited by Tregs under 
different inflammatory conditions.  
In clinical setting, therapies targeting leukocyte migration 
by using blocking antibodies against integrins or integrin 
ligands have been approved or in various phases of clinical 
trials for inflammatory bowel disease (IBD) [35, 36]. It is 
Figure 2. Anergic T cells exhibit a less migratory phenotype than their effector 
counterparts. CD4+ T cells were isolated from OVA323-339-TCR transgenic DO11.10 mice by
magnetic beads-conjugated antibodies as per manufacturer’s negative selection protocol 
(Miltenyi Biotech). Activated effector T cells (Teff) were generated by incubating isolated 
CD4+ T cells with irradiated APCs at the presence of OVA (200 g/mL) for 3 days. Anergic T 
cells were induced by the above culture condition with the addition of anti-CD80 and 
anti-CD86 blocking Abs (10 g/mL). At 72hr after culture, cells were harvested for further 
assays. (A) CD80/CD86 blockage induced immunosuppressive anergic T cells. 
Immunosuppressive effect of the anergic T cells were examined by co-incubating the 
anergized T cells with freshly isolated DO11.10 CD4+ T cells and irradiated APCs at the 
presence of OVA. Cell proliferation was detected by H3 incorporation assay at 72 hr of 
culture; (B) Anergic T cells are less migratory than activated Teff under flow assay. Cells 
harvested after 72-hr culture were enumerated and flowing through cytokine-stimulated or 
resting endothelial monolayer under physiologic shear stress of 1.5 dynes/cm2 and cell 
adhesion was enumerated as described [25]. 
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noteworthy that aggravated colitis was ever observed in a 
small percentage of ulcerative colitis patients treated with 
47 Ab (vedolizumab) 
[37] or β7 integrin Ab (etrolizumab)
[38]. Considering the role of Treg migration phenotypes in
their immune suppressive function as well as the regulatory
effects of Tregs over the EC and epithelial cells, it is possible
that excessive inhibition of integrin function prevents tissue
trafficking of not only the inflammatory leukocytes but also
immune regulatory Tregs that outweighs the beneficial
effects of decreased inflammatory cell recruitment into the
intestine mucosa and eventually caused the exacerbation of
colitis.
Conclusions 
Cell-based therapy and therapeutic measures harnessing 
leukocyte migration are two main themes of optimistic 
potential to bring basic immunology bench works into 
bedside treatments. Tregs are in the center stage of this new 
therapeutic modality due to their immune regulatory function 
and the feasibility to be modulated to work for both sides, i.e. 
induction of tolerance or breakthrough. We and others have 
demonstrated a crucial role for Tregs to be positioned in the 
right anatomic sites for optimal immune regulation. 
Individual Treg subsets with distinct migration phenotypes, 
the nature and the stage of the immune response, and the 
intervention strategies to be undertaken are keys to success. 
As much as therapies aimed at targeting leukocyte migration 
have gained some success in IBD and application of this new 
therapeutic modality in other inflammatory diseases to come, 
the impact attributed to alteration in Treg migratory 
phenotype and migration-related immune regulation as 
exerted by Tregs during immune suppression should not be 
overlooked.   
Conflicting interests 
The authors have declared that no conflict of interests 
exists. 
Acknowledgements 
We are grateful for the funding of this work from the 
Ministry of Science and Technology, Taiwan 
(NSC96-2314-B-002-037-MY3) & National Taiwan 
University Hospital (NTUH 105-04). We also thank Ms. 
Yu-Ka Hsiao for helping with the cartoon drawing. 
Abbreviations 
Tregs: regulatory T cells; EC: endothelial cells; APCs: 
antigen-presenting cells; DCs: dendritic cells; LNs: lymph 
nodes. 
References 
1. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;
206:232-259.
2. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev
Immunol 2004; 4:407-419.
3. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+
regulatory T cells in the human immune system. Nat Rev Immunol
2010; 10:490-500.
4. Caton AJ, Weissler KA. Regulatory cells in health and disease.
Immunol Rev 2014; 259:5-10.
5. Lu LF, Rudensky A. Molecular orchestration of differentiation
and function of regulatory T cells. Genes & Development 2009;
23:1270-1282.
6. Beal AM, Ramos-Hernandez N, Riling CR, Nowelsky EA, Oliver
PM. TGF-b induces the expression of the adaptor Ndfip1 to
silence IL-4 production during iTreg cell differentiation. Nat
Immunol 2012; 13:77-85.
7. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DAA.
Cutting Edge: Human regulatory T cells require IL-35 to mediate
suppression and infectious tolerance. J Immunol 2011;
186:6661-6666.
8. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et
al. Adenosine generation catalyzed by CD39 and CD73 expressed
on regulatory T cells mediates immune suppression. J Exp Med
2007; 204:1257-1265.
9. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A,
Diamantini A, Giometto R, et al. Expression of ectonucleotidase
CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and
immune suppression. Blood 2007; 110:1225-1232.
10. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann
TR. T regulatory and primed uncommitted CD4 T cells express
CD73, which suppresses effector CD4 T cells by converting
5'-adenosine monophosphate to adenosine. J Immunol 2006;
177:6780-6786.
11. Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T,
et al. Function of miR-146a in controlling Treg cell-mediated
regulation of Th1 responses. Cell 2010; 142:914-929.
12. Jalkanen S, Reichert RA, Gallatin WM, Bargatze RF, Weissman
IL, Butcher EC. Homing receptors and the control of lymphocyte
migration. Immunol Rev 1986; 91:39-60.
13. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues.
Immunity 2014; 41:694-707.
14. Huehn J, Hamann A. Homing to suppress: address codes for Treg
migration. Trends in Immunology 2005; 26:632-636.
15. Mottet C, Uhlig HH, Powrie F. Cutting Edge: Cure of colitis by
CD4+CD25+ regulatory T cells. J Immunol 2003; 170:3939-3943.
16. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof
A, et al. Migration matters: regulatory T cell
compartmentalization determines suppressive activity in vivo.
Blood 2005; 106:3097-3104.
17. Denning TL, Kim G, Kronenberg M. Cutting Edge: CD4+CD25+
regulatory T cells impaired for intestinal homing can prevent
colitis. J Immunol 2005; 174:7487-7491.
Inflammation & Cell Signaling 2017; 4: e1267. doi: 10.14800/ics.1267; © 2017 by Miao-Tzu Huang, et al.
http://www.smartscitech.com/index.php/ics 
Page 6 of 6 
18. Ochando JC, Yopp AC, Yang Y, Garin A, Li Y, Boros P, et al.
Lymph node occupancy is required for the peripheral development
of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005;
174:6993-7005.
19. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Chen D, et al.
CD4+CD25+CD62+ T-regulatory cell subset has optimal
suppressive and proliferative potential. American Journal of
Transplantation 2004; 4:65-78.
20. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The
subpopulation of CD4+CD25+ splenocytes that delays adoptive
transfer of diabetes expresses L-selectin and high levels of CCR7.
J Immunol 2002; 169:2461-2465.
21. Dvalos-Misslitz AC, Rieckenberg J, Willenzon S, Worbs T,
Kremmer E, Bernhardt G, et al. Generalized multi-organ
autoimmunity in CCR7-deficient mice. Eur J Immunol 2007;
37:613-622.
22. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A.
CCR7 is required for the in vivo function of CD4+ CD25+
regulatory T cells. J Exp Med 2007; 204:735-745.
23. Wheeler KM, Samy ET, Tung KSK. Cutting Edge: Normal
regional lymph node enrichment of antigen-specific regulatory T
cells with autoimmune disease-suppressive capacity. J Immunol
2009; 183:7635-7638.
24. Samy ET, Parker LA, Sharp CP, Tung KSK. Continuous control
of autoimmune disease by antigen-dependent polyclonal
CD4+CD25+ regulatory T cells in the regional lymph node. J Exp
Med 2005; 202:771-781.
25. Huang MT, Lin BR, Liu WL, Lu CW, Chiang BL. Lymph node
trafficking of regulatory T cells is prerequisite for immune
suppression. J Leukoc Biol 2016; 99:561-568.
26. Zhang N, Schroppel B, Lal G, Jakubzick C, Mao X, Chen D, et al.
Regulatory T cells sequentially migrate from inflamed tissues to
draining lymph nodes to suppress the alloimmune response.
Immunity 2009; 30:458-469.
27. Mirenda V, Millington O, Lechler RI, Scott D, Hernandez-Fuentes
MP, Read J, et al. Tolerant T cells display impaired trafficking
ability. Eur J Immunol 2005; 35:2146-2156.
28. Agenes F, Bosco N, Mascarell L, Fritah S, Ceredig R. Differential
expression of regulator of G-protein signalling transcripts and in 
vivo migration of CD4+ naive and regulatory T cells. Immunology 
2005; 115:179-188. 
29. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A.
Homeostasis and anergy of CD4+CD25+ suppressor T cells in
vivo. Nat Immunol 2002; 3:33-41.
30. James MJ, Belaramani L, Prodromidou K, Datta A, Nourshargh S,
Lombardi G, et al. Anergic T cells exert antigen-independent
inhibition of cell-cell interactions via chemokine metabolism.
Blood 2003; 102:2173-2179.
31. Nourshargh S, Marelli-Berg FM. Transmigration through venular
walls: a key regulator of leukocyte phenotype and function.
Trends in Immunology 2005; 26:157-165.
32. Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G,
Colombo PC, et al. Alloantigen specific CD8+CD28- FOXP3+ T
suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells,
inhibiting alloreactivity. Int Immunol 2004; 16:1055-1068.
33. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini
R, et al. High expression of ILT3 and ILT4 is a general feature of
tolerogenic dendritic cells. Transplant Immunology 2003;
11:245-258.
34. Zhang HL, Zheng YJ, Pan YD, Xie C, Sun H, Zhang YH, et al.
Regulatory T-cell depletion in the gut caused by integrin b7
deficiency exacerbates DSS colitis by evoking aberrant innate
immunity. Mucosal Immunol 2016; 9:391-400.
35. Cominelli F. Inhibition of leukocyte trafficking in inflammatory
bowel disease. N Engl J Med 2013; 369:775-776.
36. Rivera-Nieves J. Strategies that target leukocyte traffic in
inflammatory bowel diseases: recent developments. Current
Opinion in Gastroenterology 2015; 31:441-448.
37. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P,
McDonald JWD, et al. Treatment of ulcerative colitis with a
humanized antibody to the a4b7 integrin. N Engl J Med 2005;
352:2499-2507.
38. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC,
Bressler B, et al. A randomised phase I study of etrolizumab
(rhuMAb b7) in moderate to severe ulcerative colitis. Gut 2013;
62:1122-1130.
